Summary:
A nationwide clinical trial led by researchers at the University of Colorado Boulder and Massachusetts General Hospital reveals that a free, online mindfulness program significantly reduces the risk of postpartum depression recurrence. Known as Mindful Mood Balance for Moms (MMB for Moms), the eight-session digital platform decreased depression relapse by 26% up to six months postpartum among at-risk mothers, offering an accessible, drug-free prevention alternative.
Key Facts:
- 26% Reduction in Relapse: In a randomized controlled trial of 500 expectant mothers across all 50 states, women using the digital mindfulness platform experienced a 26% lower rate of depression recurrence compared to usual care.
- Non-Pharmacological Access: The self-paced digital intervention integrates Mindfulness-Based Cognitive Therapy (MBCT) principles, peer videos, and audio practices to overcome barriers of stigma, cost, and rural therapist shortages.
- Dual Protection for Stress & Anxiety: Beyond preventing major depressive episodes through six months postpartum, participants reported significant reductions in everyday anxiety and perceived maternal stress.
Source: University of Colorado Boulder / Massachusetts General Hospital
Perinatal depression, affecting women during pregnancy or throughout the first year following childbirth, strikes approximately one in five mothers. For women carrying a prior clinical history of depressive illness, the recurrence rate surges to an alarming 77%. The condition carries heavy burdens, from chronic insomnia and emotional despair to impaired parent-infant attachment.
While antidepressant medications serve as a conventional maintenance strategy to prevent recurrence, clinical studies show that most expectant mothers prefer psychotherapy over pharmacotherapy. Due to safety concerns, roughly half of women discontinue or reduce their antidepressant dosage upon becoming pregnant, sharply elevating their vulnerability to a full-blown relapse. Concurrently, geographical barriers, high therapy costs, mental health stigma, and severe provider shortages prevent many from accessing specialized maternal psychological support.
To close this therapeutic gap, an interdisciplinary research team led by the University of Colorado Boulder and Massachusetts General Hospital developed and clinically evaluated Mindful Mood Balance for Moms (MMB for Moms)—a scalable, free online platform adapted from evidence-based Mindfulness-Based Cognitive Therapy (MBCT).
Publishing in The Lancet Public Health, the investigators demonstrated that the self-paced digital course cut postpartum depression relapse rates by 26% compared to standard care alone.
Testing Digital Mindfulness Across All 50 States
The randomized controlled trial enrolled 500 pregnant women across the United States who had a documented history of major depressive episodes and had previously used or were currently taking antidepressants. At baseline recruitment, none of the participants were in an active depressive episode.
Participants were randomized into two arms:
- The Intervention Cohort: Completed the 12-week, eight-session digital MMB for Moms program, supported by periodic coaching check-ins.
- The Control Cohort: Continued receiving their standard obstetric and psychiatric care.
Researchers tracked participants through six months postpartum, evaluating depressive relapse alongside secondary measures of maternal stress and anxiety.
The digital curriculum blends cognitive behavioral restructuring with guided mindfulness practices. Modules instruct mothers on how to identify automatic negative thought loops, recognize early warning signs of mood deterioration, navigate self-judgment with self-compassion, and practice mindfulness while holding or feeding their newborn.
“When it comes to mitigating depression relapse, new and expectant moms need to have choices, and for many, there aren’t a lot,” said first author Sona Dimidjian, PhD, professor in the Department of Psychology and Neuroscience and director of the Renée Crown Wellness Institute at CU Boulder. “This study used the rigorous tools of science to identify a non-pharmacological approach that works.”
Bridging Access Barriers in Perinatal Care
Beyond achieving a double-digit reduction in clinical relapse, the program provided substantial protection against everyday anxiety and postpartum stress. Because three-quarters of participants in both arms maintained their prescribed antidepressant regimens during the trial, the results show that digital mindfulness acts as an effective non-pharmacological adjunct to pharmaceutical treatment, while also providing a viable standalone path for women seeking non-drug alternatives.
“There is a stereotype that pregnancy is the happiest time in a woman’s life. It is for some. But it can also be a time that brings depression, anxiety and stress,” Dimidjian noted. “New moms often feel as if everyone else has it figured out and they don’t. We try to prepare them to respond in these moments with care and kindness toward themselves.”
Senior author Lee Cohen, MD, director of the Ammon-Pinizzotto Center for Women’s Health at Massachusetts General Hospital, emphasized that the digital nature of the tool directly dismantles structural inequities in maternal healthcare.
“To a large extent, we have failed moms across America by not attending to this issue adequately,” Dr. Cohen said. “We have a lot of tools, but we have failed to enhance access to everyone who needs them. What we do know now is that for patients looking for a non-pharmacologic alternative to mitigate their risk for recurrence of depression, this program helps.”
Long-Term Resilience for Families
Because earlier research into in-person MBCT has documented durable protective benefits against depressive relapse for up to two years, the investigators anticipate that digital mindfulness training may confer lasting emotional stability well beyond the postpartum window.
Dr. Dimidjian and her colleagues are now preparing long-term observational studies to track the developmental trajectories of children born to mothers who completed the program, investigating whether early maternal emotional resilience creates a positive developmental ripple effect that buffers offspring against stress vulnerability.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neurotech and schizophrenia Research:
- Media Contact: Lisa Marshall
- Source: University of Colorado
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Lancet Public Health (Oct 1, 2026). “Outcomes of Mindful Mood Balance for Moms, online mindfulness-based cognitive therapy for perinatal depressive relapse prevention in the USA: a two-arm, single-blind, pragmatic randomised clinical trial.” Authors: Sona Dimidjian, Robert Gallop, Sherryl H Goodman, Zindel Segal, Marlene P Freeman, Laurel M Hicks, Christopher Mellinger, Kalin Ellison, Katherine Anne Yu Dunn, Joseph Levy, Laurel E Kordyban, Anne Fritzson, Charlotte Clifford, Eileen Nolan, Rachel Vanderkruik, Rebecca Wales, and Lee Cohen.
- DOI: 10.1016/S2468-2667(26)00184-2
Abstract
Outcomes of Mindful Mood Balance for Moms, online mindfulness-based cognitive therapy for perinatal depressive relapse prevention in the USA: a two-arm, single-blind, pragmatic randomised clinical trial
Background
Effective and accessible approaches to prevent depressive relapse and reduce symptoms are crucial for addressing the major public health problem of depression among perinatal women. We aimed to evaluate the effectiveness of Mindful Mood Balance (MMB) for Moms plus usual care (hereafter MMB for Moms)—a web-based mindfulness-based cognitive therapy programme customised for perinatal women—compared with usual care only, in reducing depressive relapse and symptoms.
Methods
This single-blind, randomised clinical trial was done across the USA, in euthymic pregnant women with recurrent depression who were on recent or current antidepressant medication. Recruitment occurred from March 7, 2019, to July 8, 2020 (data collection was completed Sept 12, 2021). Participants were randomly assigned to MMB for Moms, or usual care. Primary outcomes were reduction in depressive relapse risk and symptom burden, assessed using the Mini International Neuropsychiatric Interview and Patient Health Questionaire-9, respectively, across the study period. Outcomes were assessed from baseline until 6-months postpartum in three phases (intervention, end of intervention to delivery, and postpartum). The trial was registered with ClinicalTrials.gov, NCT03623620, and is complete.
Findings
Participants were recruited between March 7, 2019, and July 8, 2020. Data from 500 randomly assigned participants (mean age 32 years [SD 4·5] and mean 11·5 [2·8] weeks gestation), were analysed as the intention-to-treat sample. Of the 500 participants (249 assigned to MMB for Moms and 251 assigned to usual care), 383 [77%] provided assessment data at 3 months and 389 [78%] at 6 months postpartum. MMB for Moms had significantly lower risk of depressive relapse compared with usual care during the full trial period (up to 6 months postpartum): 81 (33%) of 249 participants assigned to MMB for Moms and 111 (44%) of 251 participants in usual care had depressive relapse (hazard ratio 0·74 [95% CI 0·56–0·99]; p=0·045; adjusted false discovery rate p=0·045). MMB for Moms was also associated with a significant reduction in depression symptom burden during the 12 week intervention phase (average decrease of 0·75 [SE 0·13] in the MMB for Moms group and 0·31 [0·13] in the usual care group) but not during the full trial period (average decrease of 0·61 [SE 0·18] in the MMB for Moms group and 0·54 [0·17] in the usual care group).
Interpretation
MMB for Moms resulted in lower risk of relapse compared with usual care, and lower depression symptom burden during the intervention phase, potentially offering an effective non-pharmacological support option for depression relapse prevention during the perinatal period with positive implications for public health practice.
Funding
US National Institutes of Health and US National Institute of Mental Health.
